It's been exciting to bring this next chapter of Mednet into the conference setting and connect with more than 200 attendees so far.
We're open through the last day today and grateful to everyone who has visited us.
#AIMW26 #AAIM #AcademicMedicine #MedicalEducation #GME #AIinMedicine
A big milestone for Mednet: our first-ever booth as a company at AAIM Week.
It's been exciting to meet people in person, introduce Mednet AI, and hear thoughtful feedback from the community.
#AIMW26 #AAIM #AcademicMedicine #MedicalEducation #GME #AIinMedicine
The AI is only as good as the knowledge behind it.
Mednet AI is a clinical assistant built on a foundation ten years in the making — 40,000+ physicians and 3,400 academic experts.
➝ www.themednet.org?utm_source=b...
#MednetAI #MedSky #AIinHealthcare
"Game-changer compared to traditional LLMs."
— Panicker Renni Robinson, MD, Cardiology Fellow
That's what Mednet AI was built for. Evidence + real expert opinion, combined. Free for all US physicians. ➝ www.themednet.org?utm_source=b...
#MednetAI #MedSky #AIinHealthcare
Most clinical assistants answer: what does the research say?
Mednet AI answers: what do experienced physicians actually do?
There's a difference. ➝ www.themednet.org?utm_source=b...
#MednetAI #MedSky #AIinHealthcare
We've got big news!!
Mednet AI is now live — a clinical assistant informed by 10 years of real-world conversations from 40,000+ physicians, combined with the best of medical research.
Free for all US physicians. Ask us anything. ➝ tinyurl.com/2jdzf75x
#MednetAI #AI #AIinHealthcare #ClinicalAI
@themednet.bsky.social has a new search ability making it even easier to find answers from colleagues. If not answered in the past, ask a new question to get answers from experts you trust: blog.themednet.org/the-new-medn...
New #LetsTalkID! @paulsaxmd.bsky.social talks w/ @pjpass.bsky.social, a med-peds ID physician at @dartmouthhealth.bsky.social & ID editor of @themednet.bsky.social, about finding trusted expert guidance beyond AI & how clinician communities help shape real-world practice.
Transcript: bit.ly/3NcrZhx
New on IDSA - Paul Sax, MD interviews Patrick Passarelli, MD (Dartmouth-Hitchcock; ID editor @Mednet) on getting expert guidance beyond AI + what makes a great clinical question.
www.idsociety.org/multimedia/p...
#MedEd #InfectiousDiseases
In mCRPC patients who had an initial response to Pluvicto but progress within 12 months, where do you position PSMA radioligand retreatment relative to other next-line systemic options in your sequencing strategy?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=27604"
Link to relevant Q&A:
What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=20197"
The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Radiopharmaceutical Retreatment (Plenary II) just concluded.
Dr. Ana Kiess is answering questions now on theMednet.
Head to the Q&A → www.themednet.org/v2/programs/199/questions?mode=question&questionId=20197
Link to relevant Q&A:
Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=27603
Link to relevant Q&A:
Can you give Pluvicto with concurrent palliative EBRT?
www.themednet.org/v2/programs/199/questions?mode=question&questionId=17105
The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Clinical Outcomes among Patients Treated with Lu-PSMA-617 and EBRT for Oligometastatic Prostate Cancer just concluded.
Dr. Neil K Taunk is answering questions now on theMednet.
Links to relevant Q&A:
When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27602
Links to relevant Q&A:
Do you modify dosing and monitoring of Lu-177–PSMA therapy for patients with prior large-field RT involving substantial active marrow compared with patients who only had focal bone SBRT? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27601
The American Society for Radiation Oncology (ASTRO) #MRPTS26 plenary session on Hematologic Toxicity Outcomes of Lu-PSMA-617 in Patients Previously Treated with EBRT for Oligometastatic Disease just concluded.
Drs. Neil K Taunk & Krishnan R Patel are answering questions now on theMednet.
Links to relevant Q&A:
How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=27599
Links to relevant Q&A:
For patients starting Pluvicto, do you have patients stop their ARPI? - www.themednet.org/v2/programs/199/questions?mode=question&questionId=26213
ASTRO plenary session on Safety and Efficacy of Lu-177 PSMA-617 Versus Established Therapies in mCRPC: Pooled Evidence from Randomized Phase II/III Trials just concluded.
Dr. John Nikitas is answering questions now on theMednet.
Head to the Q&A → www.themednet.org/v2/programs/199/questions
Join the conversation to share perspectives, ask follow-up questions, and see how others are interpreting the findings.
Join the Conversation: www.themednet.org/v2/programs/...
Keep the Conversation Going with theMednet
We’re hosting dedicated Q&A on theMednet for studies featured in this week’s Plenary and Clinical Trials sessions at the ASTRO 2026 Multidisciplinary Radiopharmaceutical Therapy Symposium in Palm Desert, CA.
#MRPTS26
From Dr. Paul Sax’s NEJM blog (HIV and ID Observations): when the question isn’t “What do the guidelines say?” but “What would you actually do?”
Read the blog here: blogs.nejm.org/hiv-id-obser...
#InfectiousDiseases #NEJM #theMednet
Meet the team behind theMednet
Introducing Dan Ricotta, MD — Medical Director, General Internal Medicine and Geriatrics at theMednet, and Associate Professor of Medicine at Harvard Medical School.
Join the peer-to-peer conversation on theMednet.org.
How do you explain the use of an AI scribe to patients?
Join the Conversation: www.themednet.org/v2/question/...
#Psychiatry #HealthAI #DigitalHealth #PatientPrivacy #ClinicalDocumentation #PatientExperience